Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT 2c antagonist, S32006

European Journal of Pharmacology

Volumn 674, Issue 1, 2011, Pages 27-32

  Norman, Trevor R ^a   Cranston, Ingrid ^a   Irons, Jeremy A ^a   Gabriel, Cecilia ^b   Dekeyne, Anne ^c   Millan, Mark J ^c   Mocaër, Elisabeth ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Fondation de France   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT 2C antagonism; agomelatine; antidepressant; behaviour; depression models; imipramine; melatonin; olfactory bulbectomy; open field; S32006; Sprague Dawley rat

Indexed keywords

AGOMELATINE; IMIPRAMINE; MELATONIN; S 32006; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; HYPERACTIVITY; MALE; MOBILIZATION; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ACETAMIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; HYPERKINESIS; INDOLES; MALE; MELATONIN; OLFACTORY BULB; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 82255196037     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.10.010     Document Type: Article

References (73)

1. V. Audinot, F. Mailliet, C. Lahaye-Brasseur, A. Bonnaud, A. Le Gall, and C. Amosse New selective ligands of human cloned melatonin MT1 and MT2 receptors Naunyn Schmiedebergs Arch. Pharmacol. 367 2003 553 561 (Pubitemid 36829452)
2. M. Banasr, M. Hery, E. Mocaër, and A. Daszuta Agomelatine, a new antidepressant drug, increases cell proliferation, maturation and survival of newly generated granule cells in adult hippocampus Biol. Psychiatry 59 2006 1087 1096
3. N. Barden, E. Shink, M. Labbe, R. Vacher, J. Rochford, and E. Mocaer Antidepressant action of agomelatine (S 20098) in a transgenic mouse model Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 908 916 (Pubitemid 41080111)
4. V. Bertaina-Anglade, C. Drieu, P.A. Boyer, and E. Mocaer Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model Behav. Pharmacol. 17 2006 703 713
5. M. Bourin, E. Mocaer, and R. Porsolt Antidepressant-like activity of S-20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors J. Psychiatry Neurosci. 29 2004 126 133 (Pubitemid 38570217)
6. J.N. Bunney, and S.G. Potkin Circadian abnormalities, molecular clock genes and chronobiological treatments in depression Br. Med. Bull. 86 2008 23 32 (Pubitemid 351809636)
7. G.D. Burrows, T.R. Norman, and F.K. Judd Definition and differential diagnosis of treatment resistant depression Int. Clin. Psychopharmacol. 2 1994 5 10 (Pubitemid 24199851)
8. K.D. Cairncross, B. Cox, C. Forster, and A.F. Wren Olfactory projection systems, drugs and behaviour: A review Psychoneuroendocrinology 4 1979 253 272 (Pubitemid 10209956)
9. F. Calabrese, R. Molteni, C. Gabriel, E. Mocaer, G. Racagni, and M. Riva Modulation of neuroplastic molecules in selected brain regions after chronic administration of the novel antidepressant agomelatine Psychopharmacology 215 2011 267 275
10. E. Castren, V. Voikar, and T. Rantamaki Role of neurotrophic factors indepression Curr. Opin. Pharmacol. 7 2007 18 21
11. B. Chanrion, C. Mannoury la Cour, S. Gavarini, M. Seimandi, L. Vincent, J.F. Pujol, J. Bockaert, P. Marin, and M.J. Millan Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction Mol. Pharmacol. 73 2008 748 757
12. G. Dagyte, A. Trentani, F. Postema, P.G. Luiten, G.A. Den Boer, C. Gabriel, E. Mocaër, P. Meerlo, and E.A. Van der Zee The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats CNS Neurosci. Ther. 16 2010 195 207
13. G. Dagyte, I. Crescente, F. Postema, L. Seguin, C. Gabriel, E. Mocaër, J.A. Boer, and J.M. Koolhaas Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress Behav. Brain Res. 218 2011 121 128
14. C. De Bodinat, B. Guardiola-Lemaitre, E. Mocaër, and P. Renard Agomelatine, the first melatonergic antidepressant: discovery, characterization and development Nat. Rev. Drug Discov. 9 2010 628 642
15. M.W. De Wries, and F.P. Peeters Melatonin as a therapeutic agent in the treatment of sleep disturbances in depression J. Nerv. Ment. Dis. 185 1997 201 202 (Pubitemid 27508673)
16. A. Dekeyne, and M.J. Millan Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization Psychopharmacology 203 2009 329 341
17. 2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models Psychopharmacology (Berl) 199 2008 549 568
18. B.C. Detanico, A.L. Piato, J.J. Freitas, F.L. Lhullier, M.P. Hidalgo, W. Caumo, and E. Elisabetsky Antidepressant-like effects of melatonin in the mouse chronic mild stress model Eur. J. Pharmacology 607 2009 121 125
19. O.T. Dolberg, S. Hirschmann, and L. Grunhaus Melatonin for the treatment of sleep disturbances in major depressive disorder Am. J. Psychiatry 155 1998 1119 1121 (Pubitemid 28357744)
20. R.S. Duman Depression: a case of neuronal life and death? Biol. Psychiatry 56 2004 140 145 (Pubitemid 38969145)
21. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol. Psychiatry 59 2006 1116 1127
22. W.C. Duncan Circadian rhythms and the pharmacology of affective illness Pharmacol. Ther. 71 1996 253 312
23. J. Emens, A. Lewy, J.M. Kinzie, D. Arntz, and J. Rough Circadian misalignment in major depressive disorder Psychiatry Res. 168 2009 259 261
24. 2C receptors to multiple actions of central serotonin systems Eur. J. Pharmacol. 488 2004 1 9 (Pubitemid 38388517)
25. G.M. Goodwin, R. Emsley, S. Rembry, and F. Rouillon Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial J. Clin. Psychiatry 70 2009 1128 1137
26. J.A. Gray, and B. Lalljee Sex differences in emotional behaviour in the rat: correlation between open field defaecation and active avoidance Anim. Behav. 2 1974 856 861
27. A. Hale, R. Corral, O. Mencacci, J. Saiz Ruiz, C. Albarran Severo, and C. Gentil Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study Int. Clin. Psychopharmacol. 25 2010 305 314
28. C.S. Hall Emotional behaviour in the rat. I. Defecation and urination as measures of individual differences in emotionality J. Comp. Physiol. 18 1934 385 403
29. M.A. Hirschfeld, and A.F. Schatzberg Long-term management of depression Am. J. Med. 97 1994 6A33S-6A38S
30. S. Jancsar, and B.E. Leonard Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat Prog. Neuropsychopharmacol. Biol. Psychiatry 8 1984 263 269 (Pubitemid 14101493)
31. S. Jancsar, and B.E. Leonard The effect of (+/-)mianserin and its enantiomers on the behavioural hyperactivity of the olfactory-bulbectomized rats Neuropharmacology 23 1984 1065 1070 (Pubitemid 14008975)
32. S. Kasper, G. Hajak, K. Wulff, W.J.G. Hoogedijk, A.L. Montejo, M.-A. Quera-Salva, A.M. Wirz-Justice, F. Picarel-Blanchot, and F.J. Bayle Efficacy of the novel antidepressant agomelatine on the circadian-rest activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomised, double-blind comparison with sertraline J. Clin. Psychiatry 71 2010 109 120
33. J.P. Kelly, T.R. Norman, A. O'Halloran, and B.E. Leonard Home cage and open field locomotor activity in singly housed olfactory bulbectomised rats Med. Sci. Res. 24 1996 335 337 (Pubitemid 26184152)
34. J.P. Kelly, A.S. Wryn, and B.E. Leonard The olfactory bulbectomised rat as a model of depression: an update Pharmacol. Ther. 74 1997 299 316 (Pubitemid 27425352)
35. G. Kempermann The neurogenic reserve hypothesis: what is adult hippocampal neurogenesis good for? Trends Neurosci. 31 2008 163 169
36. B.E. Leonard, and W.T. O'Connor The effect of chronically administered mianserin, 8-hydroxymianserin and desmethylmianserin on the open field behaviour and noradrenaline metabolism in the olfactory bulbectomized rat Neuropsychobiology 18 1987 118 121
37. A.J. Lewy, and R.L. Sack Minireview: light therapy and psychiatry Proc. Soc. Exp. Biol. Med. 183 1989 11 18
38. A.J. Lewy, B.J. Lefler, J.S. Emens, and V.K. Bauer The circadian basis of winter depression Proc. Natl. Acad. Sci. 103 2006 7414 7419 (Pubitemid 43727847)
39. H. Loo, A. Hale, and H. D'haenen Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study Int. Clin. Psychopharmacol. 1 2002 239 247
40. M. Mantovani, R. Pertile, J.B. Calixto, A.R. Santos, and A.L. Rodrigues Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway Neurosci. Lett. 343 2003 1 4 (Pubitemid 36577198)
41. D. Marazziti, G. Consoli, M. Picchetti, M. Carlini, and L. Faravelli Cognitive impairment in major depression Eur. J. Pharmacol. 626 2010 83 86
42. C. McGrath, and T.R. Norman The effect of venlafaxine treatment on the behaviour and neurochemical changes in the olfactory bulbectomised rat Psychopharmacology (Berl) 36 1998 394 401 (Pubitemid 28189670)
43. V. Micale, A. Arezzi, L. Rampello, and F. Drago Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission Eur. Neuropsychopharmacol. 16 2006 538 545 (Pubitemid 44311002)
44. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Therapie 60 2005 441 460
45. M.J. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2006 135 370
46. M.J. Millan, A. Gobert, J.M. Rivet, A. Adhumeau-Auclair, D. Cussac, A. Newman-Tancredi, A. Dekeyne, J.P. Nicolas, and F. Lejeune Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.F Eur. J. Neurosci. 12 2000 1079 1095 (Pubitemid 30168787)
47. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways J. Pharm. Exp. Ther. 306 2003 954 964 (Pubitemid 37025301)
48. M.J. Millan, M. Brocco, A. Gobert, and A. Dekeyne Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT(2C) receptor blockade Psychopharmacology 177 2005 1 12 (Pubitemid 40228283)
49. 2Creceptors Int. J. Neuropsychopharmacol. 15 2010 1 16
50. H.J. Möller Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment World J. Biol. Psychiatry 9 2008 102 114
51. P. Monteleone, and M. Maj The circadian basis of mood disorders: recent developments and treatment implications Eur. Neuropsychopharmacol. 18 2008 701 711
52. T.R. Norman Prospects for the treatment of depression Aust. NZ J. Psychiatry 40 2006 394 401
53. T.R. Norman Dysfunctional circadian rhythms and mood disorders: Opportunities for novel therapeutic approaches Mod. Trends Pharmacopsychiatry 27 2010 32 52
54. T.R. Norman, and J.S. Olver Continuation treatment of major depressive disorder: Is there a case for duloxetine? Drug Des., Dev. Ther. 4 2010 1 13
55. W.T. O'Connor, and B.E. Leonard Effect of chronic administration of the 6-aza analogue of mianserin (Org 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the "open field" apparatus Neuropsychobiology 25 1986 267 270 (Pubitemid 16165423)
56. J.S. Olver, G.D. Burrows, and T.R. Norman Third generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 15 2001 941 954 (Pubitemid 34017003)
57. D.H. Overstreet, O. Pucilowski, M.C. Retton, P. Delagrange, and B. Guardiola-Lemaitre Effects of melatonin receptor ligands on swim test immobility NeuroReport 9 1998 249 253 (Pubitemid 28081397)
58. E. Païzanis, T. Renoir, V. Lelievre, F. Saurini, M. Melfort, C. Gabriel, N. Barden, E. Mocaër, M. Hamon, and L. Lanfumey Behavioural and neuroplastic effects on the new generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice Int. J. Neuropsychopharmacol. 13 2010 759 774
59. M. Papp, P. Gruca, P.-A. Boyer, and E. Mocaer Effect of agomelatine in the chronic mild stress model of depression in the rat Neuropsychopharmacology 28 2003 694 703
60. M. Papp, E. Litwa, P. Gruca, and E. Mocaer Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety Behav. Pharmacol. 17 2006 9 18 (Pubitemid 43068380)
61. B.L. Parry, W.B. Mendelson, W.C. Duncan, D.A. Sack, and T.A. Wehr Longitudinal sleep EEG, temperature and activity measurements across the menstrual cycle in patients with premenstrual depression and age-matched controls Psychiatry Res. 30 1989 285 303 (Pubitemid 20015694)
62. Q. Rainer, L. Xia, J.P. Guilloux, C. Gabriel, E. Mocaer, R. Hen, E. Enhamre, A.M. Gardier, and D.J. David Beneficial behavioral and neurogenic effects of agomelatine in a model of depression/anxiety Int. J. Neuropsychopharmacol. 8 2011 1 15
63. G. Ramirez-Rodriguez, F. Klempin, H. Babu, G. Benitez-King, and G. Kempermann Melatonin modulates cell survival of new neurons in the hippocampus of adult mice Neuropsychopharmacology 34 2009 2180 2191
64. J.R. Redman, B. Guardiola-Lemaitre, M. Brown, P. Delagrange, and S.M. Armstrong Dose-dependent effects of S-20098, a melatonin agonist on the direction of re-entrainment of rat circadian rhythms Psychopharmacology 118 1995 385 390
65. S. Rosenzweig-Lipson, A. Sabb, G. Stack, P. Mitchell, I. Lucki, J.E. Malberg, S. Grauer, J. Brennan, J.F. Cryan, S.J. Sukoff Rizzo, J. Dunlop, J.E. Barett, and K.L. Marquis Antidepressant-like effects of the novel, selective, 5HT2C receptor agonist WAY-163909 in rodents Psychopharmacology 192 2007 159 170 (Pubitemid 46669211)
66. A. Sahay, and R. Hen Adult hippocampal neurogenesis in depression Nat. Neurosci. 10 2007 1110 1115 (Pubitemid 47339960)
67. C. Song, and B.E. Leonard The effect of olfactory bulbectomy in the rat, alone or in combination with antidepressants and endogenous factors, on immune function Hum. Psychopharmacol. 10 1995 7 18
68. C. Song, and B.E. Leonard The olfactory bulbectomised rat as a model of depression Neurosci. Biobehav. Rev. 29 2005 627 647 (Pubitemid 40755458)
69. A. Soumier, M. Banasr, S. Lortet, F. Masmejean, N. Bernard, L. Kerkerian-Le-Goff, C. Gabriel, M.J. Millan, E. Mocaër, and A. Daszuta Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant agomelatine in the adult rat hippocampus Neuropsychopharmacology 34 2009 2390 2403
70. V. Srinivasan, M. Smits, W. Spence, A.D. Lowe, L. Kayumov, S.R. Pandi-Perumal, B. Parry, and D.P. Cardinali Melatonin in mood disorders World J. Biol. Psychiatry 7 2006 138 151 (Pubitemid 44137014)
71. B. Steiniger, and B.D. Kretschmer Effects of ibotenate pedunculopontine tegmental nucleus lesions on exploratory behaviour in the open field Behav. Brain Res. 151 2004 17 23 (Pubitemid 38501424)
72. R.N. Walsh, and R.A. Cummins The open field test: A critical review Psychol. Bull. 83 1976 482 504
73. J.M. Zajecka Clinical issues in long treatment with antidepressants J. Clin. Psychiatry 61 2000 20 25 (Pubitemid 30131899)